
Ubigene gene knockout cell lines mediated by optimized CRISPR-Cas9 technology provide reliable in vitro models for investigating gene function, signaling pathways, disease mechanisms, and therapeutic targets.
ZBTB47 (zinc finger and BTB domain containing 47) encodes a zinc finger and BTB domain-containing protein predicted to function as a DNA-binding transcription factor. It is predicted to regulate RNA polymerase II-dependent transcription and to function in the nucleus. The specific target genes and biological pathways regulated by ZBTB47 remain incompletely characterized, making it relevant to studies of transcriptional regulation and gene expression.
A human hepatocellular carcinoma model, MHCC97-H was established from a highly metastatic human hepatocellular carcinoma and selected for its invasive and metastatic phenotype. The cells originated from a liver tumor of a 39-year-old male and are classified as a human liver cancer cell line. MHCC97-H is characterized by a hypotriploid karyotype and has been used in studies of hepatocellular carcinoma invasion and metastasis.
Each knockout cell line is validated by STR authentication, sterility testing (bacteria/fungi), and mycoplasma screening. Genotype is confirmed by two rounds of PCR and Sanger sequencing. Only clones that pass all QC criteria are released, ensuring reliable identity and performance for downstream applications.

Cas9 cell lines in our cell bank can stably express Cas9 protein. Each Cas9 Stable Cell Line is easy to use and enables gene knockout simply by transfecting gRNA, while transfection of gRNA and donor DNA results in gene knock-in or point mutations
These Cas9 stable cell lines have been used to construct the KO cell lines for various genes, gene KO efficiency 5-10 times improved.
Selected cells, low passages, good cell condition, high activity, applicable for all kinds of gene-editing experiments.

Targeted knockout region: EExon 2
Reference Transcript: NM_001410746
Frameshift Mutation Strategy
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use





Simply fill out the form below to leave your inquiry
— we will respond within 24 Hours.
* Name
* Institution
* Products & Services of Interest
If email is not available, how else can we reach you?
How did you hear about us?